Syndax Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SNDX research report →
Range $31 – $43
Price Chart
About the company
Syndax Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm focused on developing innovative therapies for cancer. Among its leading investigational products are SNDX-5613, currently undergoing Phase 1/2 clinical assessment, which targets the Menin-mixed lineage leukemia 1 protein interaction for treating MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML).
- CEO
- Michael A. Metzger
- IPO
- 2016
- Employees
- 298
- HQ
- New York City, NY, US
Get TickerSpark's AI analysis on SNDX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $785.05M
- P/E
- -3.88
- Fwd P/E
- 62.37
- PEG
- -0.08
- P/S
- 2.86
- P/B
- -48.08
- EV/EBITDA
- -10.75
- Div Yield
- 0.00%
- Gross Margin
- 93.69%
- Op Margin
- -61.72%
- Net Margin
- -72.38%
- ROE
- -804.38%
- ROIC
- -31.22%
Latest fiscal year · YoY change
- Revenue
- $172.35M+627.8%
- Gross Profit
- $165.38M+623.6%
- Op Income
- $-273,084,000
- Net Income
- $-285,422,000+10.5%
- EPS
- $-3.29+11.8%
- OCF Growth
- -17.5%
- FCF Growth
- -17.6%
- 52W High
- $25.59
- 52W Low
- $8.41
- 50D MA
- $14.41
- 200D MA
- $19.49
- Beta
- 0.37
- RSI (14)
- 28
- Avg Volume
- 2.62M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Syndax posted another strong quarter of rapid revenue growth, led by Revuforj and Niktimvo, while outlining a growing post-transplant tailwind and a well-funded pipeline strategy.· November 2, 2026
- Total revenue was $83.3 million, up 82% year over year, driven by Revuforj and Niktimvo growth.
- Revuforj net revenue reached $60.7 million, up 90% year over year and 11% quarter over quarter, with about 1,700 prescriptions and about 300 new patients.
- Niktimvo net revenue was $67 million, up 47% year over year and 12% quarter over quarter; collaboration revenue to Syndax was $22.6 million.
- Management said post-transplant resumption is becoming an important growth driver, with about 50% of KMT2A patients and 50% of NPM1 transplant patients resuming therapy after transplant.
- Cash and investments ended the quarter at $551 million, and 2026 total R&D plus SG&A guidance remained approximately $400 million excluding $50 million of noncash stock compensation.
Third-quarter 2026 revenue was $83.3 million, up 82% from the prior year. Revuforj net revenue was $60.7 million, up 90% year over year and 11% sequentially, while Niktimvo collaboration revenue was $22.6 million and Niktimvo net revenue was $67 million, up 47% year over year and 12% sequentially. Niktimvo margin contribution was approximately 34% in the quarter, helped by a one-time nonrecurring adjustment, and management now expects that margin contribution to run in the low-to-mid-30% range going forward. The company ended Q3 with $551 million in cash, equivalents and investments, and it reaffirmed 2026 R&D plus SG&A guidance of approximately $400 million, excluding $50 million of estimated noncash stock compensation expense. Looking ahead, management said revenue from both medicines should keep growing and move the company toward profitability.
Michael Metzger framed the quarter as evidence that Syndax is gaining both commercial scale and pipeline momentum. He emphasized Revuforj’s market leadership in relapsed/refractory NPM1 and KMT2A acute leukemia, the expected step-up from post-transplant resumption, and the company’s goal of becoming the first menin inhibitor in front-line AML. His tone was confident and upbeat, repeatedly highlighting the strength of the data package, upcoming ASH catalysts, and the potential for Revuforj to exceed $2 billion in peak annual U.S. net revenue if front-line indications are approved.
Keith Goldan highlighted a quarter with $83.3 million in total revenue, a 82% increase year over year, and broke out Revuforj at $60.7 million and Niktimvo collaboration revenue at $22.6 million. He said Niktimvo’s margin contribution was about 34% this quarter and should settle into the low-to-mid-30% range, up from the earlier 25% to 30% launch guidance, with the quarter modestly helped by a one-time adjustment. He also reaffirmed 2026 operating expense guidance of about $400 million for R&D plus SG&A, excluding $50 million of noncash stock comp, and noted the company ended with $551 million in cash, equivalents and investments. He said Syndax is fully funded for its commercial and development priorities, including the front-line revumenib and axatilimab trials and earlier pipeline work.
Analysts focused heavily on Revuforj’s growth drivers, especially the surprisingly high transplant and post-transplant maintenance rates in NPM1 and KMT2A. Management said the rising post-transplant resumption trend is real and could become a meaningful tailwind in 2027, with NPM1 now showing about a 40% transplant rate and about 50% of those patients resuming therapy, while KMT2A transplant patients are resuming at about 60% and could rise further over time. Questions also centered on the upcoming front-line data from BEAT AML and SAVE, and management said the key watchpoints are tolerability, CR rates versus historical controls, MRD eradication, and survival with longer follow-up and a larger cohort. In addition, management addressed the competitive landscape, saying they believe Revuforj’s broad clinical profile and first-mover position leave it well positioned versus future competitors.
The call reinforced that both marketed products are still growing quickly, with Revuforj showing accelerating new starts and broad adoption across account types, and Niktimvo continuing to add patients and infusions. Management also described a potentially durable growth lever in post-transplant resumption, especially as more NPM1 patients are treated earlier and move to maintenance after transplant. On top of that, the company has a sizable cash position and multiple near-term clinical catalysts, including ASH presentations and additional front-line data.
The transplant-related pause in therapy is still a near-term revenue headwind, and management acknowledged the growth from resumption will take time to fully show up in sales, likely more materially in 2027. The company is also facing a more crowded menin inhibitor landscape, and management declined to give precise timing on front-line enrollment and approval milestones. Finally, the axatilimab front-line data were pushed into 2027/2028 timing, which delays another potential growth catalyst.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 90.2%
- Shares Outstanding
- 90.03M
- Float Shares
- 81.19M
of shares held by institutions
254 13F filers
Buy/sell ratio 0.50. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 9.27M | ▲ 248.45K |
| Kynam Capital Management, LP | 8.05M | 0 |
| Vanguard Group Inc | 6.23M | ▲ 1.09M |
| Goldman Sachs Group Inc | 5.86M | ▲ 864.48K |
| State Street Corp | 4.65M | ▼ 1.01M |
| Bank Of America Corp | 4.05M | ▼ 204.74K |
| Vanguard Capital Management LLC | 3.95M | ▲ 26.04K |
| Deerfield Management Company, L.P. | 3.78M | 0 |
| Franklin Templeton Inc | 3.49M | ▲ 1.20M |
| Eversept Partners, LP | 2.80M | ▼ 87.41K |
| Hood River Capital Management LLC | 2.56M | ▲ 209.99K |
| Kingdon Capital Management, L.L.C. | 2.50M | 0 |
Held by 278 ETFs
Biggest fund positions in SNDX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 9, 26 | Ondrey Aaron | other | 270,000 |
| Nov 9, 26 | Ondrey Aaron | other | 0 |
| Oct 29, 26 | Podlesak Dennis | other | 8,000 |
| Oct 29, 26 | Podlesak Dennis | sell | 8,000 |
| Oct 29, 26 | Podlesak Dennis | other | 8,000 |
| Jul 8, 26 | Metzger Michael A | other | 32,375 |
| Jul 8, 26 | Metzger Michael A | sell | 32,375 |
| Jul 8, 26 | Metzger Michael A | other | 32,375 |
| Jun 11, 26 | Botwood Nicholas A.J. | other | 22,515 |
| Jun 12, 26 | Botwood Nicholas A.J. | other | 31,235 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our SNDX coverage
Recent articles, reports, and earnings notes.

Nordicus Partners IPO: What Investors Need to Know
Nordicus Partners Corporation (NASDAQ: NORD) is expected to list on 2026-10-30, but the company has not disclosed a price range yet. The story is less a classic IPO and more a microcap biotech holding-company setup tied to Nordic life sciences assets. Bull case: asset-backed biotech optionality; bear case: no disclosed terms, nominal revenue, and going-concern risk.

Should You Buy the Parabilis Medicines IPO? Here's the Setup
Parabilis Medicines (NASDAQ: PBLS) is expected to list on 2026-06-10, with shares priced at $17.00 to $19.00. The company is offering 25,000,000 shares and is targeting a $546,250,000 market cap. The bull case is a differentiated oncology platform; the bear case is a clinical-stage biotech with no disclosed commercial revenue.
Want a deeper read on SNDX?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Syndax Pharmaceuticals, Inc. (SNDX) Presents at UBS Global Biopharma Conference 2026 Transcript
seekingalpha.com · Nov 17
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syndax Pharmaceuticals, Inc.- SNDX
prnewswire.com · Nov 12
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syndax Pharmaceuticals, Inc.- SNDX
globenewswire.com · Nov 10
Syndax Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
globenewswire.com · Nov 9
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syndax Pharmaceuticals, Inc.- SNDX
prnewswire.com · Nov 5
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
globenewswire.com · Nov 4
Syndax Pharmaceuticals: Revuforj Shows Strong Commercial Growth, But Frontline AML Is The Key
seekingalpha.com · Nov 4
Syndax to Host ASH Investor Event in Person and via Webcast on December 14, 2026
globenewswire.com · Nov 4
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.